BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 34792133)

  • 1. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial.
    Bülow NS; Skouby SO; Warzecha AK; Udengaard H; Andersen CY; Holt MD; Grøndahl ML; Nyboe Andersen A; Sopa N; Mikkelsen ALE; Pinborg A; Macklon NS
    Hum Reprod; 2022 Jan; 37(2):309-321. PubMed ID: 34792133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial.
    Bülow NS; Warzecha AK; Nielsen MV; Andersen CY; Holt MD; Petersen MR; Sopa N; Zedeler A; Englund AL; Pinborg A; Grøndahl ML; Skouby SO; Macklon NS
    Hum Reprod; 2023 Nov; 38(11):2154-2165. PubMed ID: 37699851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.
    Massin N; Abdennebi I; Porcu-Buisson G; Chevalier N; Descat E; Piétin-Vialle C; Goro S; Brussieux M; Pinto M; Pasquier M; Bry-Gauillard H
    Hum Reprod; 2023 May; 38(5):927-937. PubMed ID: 36864699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of letrozole cotreatment on endocrinology and follicle development in women undergoing ovarian stimulation in an antagonist protocol.
    Poulsen LC; Warzecha AK; Bülow NS; Bungum L; Macklon NS; Yding Andersen C; Skouby SO
    Hum Reprod; 2022 Jun; 37(7):1557-1571. PubMed ID: 35652260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does adjuvant letrozole reduce uterine peristalsis prior to fresh embryo transfer?
    Dreyer Holt M; Warzecha AK; Bülow NS; Skouby SO; Englund ALM; Birch Petersen K; Macklon NS
    Hum Reprod Open; 2022; 2022(2):hoac011. PubMed ID: 35356508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial.
    Bosch E; Alamá P; Romero JL; Marí M; Labarta E; Pellicer A
    Hum Reprod; 2024 Feb; 39(2):393-402. PubMed ID: 38037188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
    Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
    Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve.
    Friis Wang N; Bogstad JW; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
    Hum Reprod; 2023 Sep; 38(9):1807-1815. PubMed ID: 37354554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial.
    Boudry L; Mateizel I; Wouters K; Papaleo E; Mackens S; De Vos M; Racca A; Adriaenssens T; Tournaye H; Blockeel C
    Hum Reprod; 2024 Mar; 39(3):538-547. PubMed ID: 38199789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A drop in serum progesterone from oocyte pick-up +3 days to +5 days in fresh blastocyst transfer, using hCG-trigger and standard luteal support, is associated with lower ongoing pregnancy rates.
    Uyanik E; Mumusoglu S; Polat M; Yarali Ozbek I; Esteves SC; Humaidan P; Yarali H
    Hum Reprod; 2023 Feb; 38(2):225-236. PubMed ID: 36478179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.
    Griesinger G; Blockeel C; Sukhikh GT; Patki A; Dhorepatil B; Yang DZ; Chen ZJ; Kahler E; Pexman-Fieth C; Tournaye H
    Hum Reprod; 2018 Dec; 33(12):2212-2221. PubMed ID: 30304457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of luteal serum progesterone levels on live birth rates-a prospective study of 602 IVF/ICSI cycles.
    Thomsen LH; Kesmodel US; Erb K; Bungum L; Pedersen D; Hauge B; Elbæk HO; Povlsen BB; Andersen CY; Humaidan P
    Hum Reprod; 2018 Aug; 33(8):1506-1516. PubMed ID: 29955789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
    Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
    Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically significant intra-day variability of serum progesterone levels during the final day of oocyte maturation: a prospective study with repeated measurements.
    González-Foruria I; Rodríguez I; Martínez F; Rodríguez-Purata J; Montoya P; Rodríguez D; Nicolau J; Coroleu B; Barri PN; Polyzos NP
    Hum Reprod; 2019 Aug; 34(8):1551-1558. PubMed ID: 31334546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial.
    Liu X; Wen W; Wang T; Tian L; Li N; Sun T; Wang T; Zhou H; Zhang N; Qu P; Mol BW; Li W; Shi J
    Hum Reprod; 2022 Jul; 37(8):1806-1815. PubMed ID: 35595197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles.
    Martinez F; Clua E; Roca M; Garcia S; Polyzos NP
    Hum Reprod; 2022 Nov; 37(12):2777-2786. PubMed ID: 36269092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve.
    Friis Wang N; Bogstad JW; Pors SE; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
    Hum Reprod; 2023 Apr; 38(4):716-725. PubMed ID: 36721920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosocial wellbeing shortly after allocation to a freeze-all strategy compared with a fresh transfer strategy in women and men: a sub-study of a randomized controlled trial.
    Pilegaard SP; Schmidt L; Stormlund S; Koert E; Bogstad JW; Prætorius L; Nielsen HS; la Cour Freiesleben N; Sopa N; Klajnbard A; Humaidan P; Bergh C; Englund ALM; Løssl K; Pinborg A
    Hum Reprod; 2023 Nov; 38(11):2175-2186. PubMed ID: 37742131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.